Lymphoma and Multiple Myeloma
Multiple Myeloma
1
| Disease Status and/or Stage | Relapsed or refractory |
|---|---|
| Protocol Title | A Phase II Study of VEGF Trap for the Treatment of Relapsed or Refractory Multiple Myeloma |
| PI | Ruben Niesvizky, MD |
| Contact | Mary Crann, RN |
| Key Eligibility | For patients with stage IIa or IIIa multiple myeloma with measurable disease defined by serum M protein greater than or equal to 1.0 gm/dl measured by serum protein electrophoresis or free light chain measurement of more than 200 mg/dl and/or urinary M protein excretion greater than or equal to 200 mg/24 hours. Patients must have had 2 or fewer prior therapies. Patient must have normal organ and marrow function. |
| Treatment Overview | Patients will receive a dose of VEGF Trap by infusion on Day 1 of each 14 day cycle. Patients can receive VEGF Trap until they experience progression of disease or unacceptable adverse events. |
2
| Disease Status and/or Stage | Relapsed or Refractory Multiple Myeloma |
|---|---|
| Protocol Title | Phase 1/2 Open-Label Study of the Safety and Efficacy of PD 0332991 In Combination with Bortezomib and Dexamethasone in Patients with Refractory Multiple Myeloma |
| PI | Ruben Niesvizky, MD |
| Contact | Mary Crann, RN |
| Key Eligibility | Relapsed or Refractory Multiple Myeloma after at least 2 prior therapies. All previous therapies for cancer must be discontinued for at least 4 weeks (2 weeks for lenalidomide or thalidomide) before study entry. |
| Treatment Overview | PD 0332991 will be given orally, starting on Day 1 of each cycle, once a day for 3 weeks (21 days) followed by one week (7 days) without treatment. Bortezomib and dexamethasone will be administered on Days 8, 11, 15, and 18 of Cycles 1 through 10. One cycle is defined as 4 weeks (28 days). The maximum treatment period will be 10 cycles or 280 days. |
3
| Disease Status and/or Stage | Progressive Disease after therapies with curative potential or approved salvage regimen. |
|---|---|
| Protocol Title | Phase I/II, Open-Label, Dose Escalation Study of CDX-1401 in Patients with Malignances Known to Express NY-ESO-1 |
| PI | Ellen Chung , M.D. |
| Contact | Kristen Petrillo, R.N. 212-746-5430 |
Last updated: January 5, 2011 |
 |
